Cellectar Biosciences Reports Long-Lasting Response in DLBCL Case Study
The company reported a complete response lasting more than eight years in a heavily pretreated DLBCL patient treated with iopofosine I 131.
Related stories
Origin Energy Reports 34.2% Sequential Rise in First-Quarter APLNG Revenue
Origin Energy said revenue from its stake in the Australia Pacific LNG project rose 34.2% sequentially in the first quarter, supported by higher realised oil prices on LNG sales.
H impact | EQUITY | Oct 29, 2026, 09:24 PM UTC
Walmart Introduces 89-Peso Monthly Membership in Mexico
Walmart is targeting Amazon and Mercado Libre customers with a membership priced at 89 pesos per month.
M impact | EQUITY | Oct 29, 2026, 09:24 PM UTC
Reddit Q3 Profit Rises to $283.264 Million
Reddit reported third-quarter profit of $283.264 million, or $1.40 per share, compared with $162.663 million, or $0.80 per share, a year earlier.
M impact | EQUITY | Oct 29, 2026, 09:22 PM UTC
Monolithic Power Systems Names Tony Balow CFO
M impact | EQUITY | Oct 29, 2026, 09:22 PM UTC
Illumina Says Clinical Sequencing Demand Drove Q3 2026 Earnings Beat
Illumina management attributed the company’s Q3 2026 earnings beat to clinical sequencing demand.
M impact | EQUITY | Oct 29, 2026, 09:22 PM UTC
Mondelez Q3 profit exceeds expectations as cost pressures ease
Reuters reports Mondelez International’s third-quarter profit exceeded expectations as cost pressures eased.
M impact | EQUITY | Oct 29, 2026, 09:21 PM UTC